Barclays assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Free Report) in a research report released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $78.00 price objective on the stock.
Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group increased their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Guggenheim reduced their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. HC Wainwright increased their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Finally, JonesTrading lifted their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $75.00.
Read Our Latest Research Report on ELVN
Enliven Therapeutics Stock Performance
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Sell-side analysts forecast that Enliven Therapeutics will post -1.69 earnings per share for the current year.
Insider Activity at Enliven Therapeutics
In related news, Director Mika K. Derynck sold 158,795 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the completion of the transaction, the director owned 87,373 shares of the company’s stock, valued at $5,260,728.33. This trade represents a 64.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. The trade was a 19.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 196,849 shares of company stock valued at $11,344,257 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.
Hedge Funds Weigh In On Enliven Therapeutics
Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Enliven Therapeutics during the 2nd quarter valued at about $221,255,000. Vestal Point Capital LP raised its holdings in Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Siren L.L.C. purchased a new position in Enliven Therapeutics in the first quarter worth about $29,252,000. Jupiter Topco LLC bought a new position in shares of Enliven Therapeutics in the second quarter worth approximately $30,617,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Enliven Therapeutics in the first quarter worth approximately $23,007,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.
Enliven Therapeutics Company Profile
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
